Healthcare / BiotechnologyTaipei Exchange
$74.60
-1.10 (-1.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-70.7M · quality 84.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.5%
↓Gross Margin
48.4%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.5%
FCF CAGR
—
FCF margin
-164.6%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $38.3M · net income $-82.7M · FCF $-63.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $38.3M | $38.3M | $44.2M | $51.1M | $27.6M |
| Net Income | $-82.7M | $-82.7M | $-62.1M | $-41.4M | $-60.9M |
| EBITDA | $-65.9M | $-65.9M | $-48.3M | $-30.2M | $-51.6M |
| EPS | — | — | -1.01 | -0.78 | -1.28 |
| Gross Margin | 48.4% | 48.4% | 59.2% | 76.6% | 48.6% |
| Operating Margin | -242.8% | -242.8% | -150.3% | -88.4% | -227.2% |
| Net Margin | -216.1% | -216.1% | -140.4% | -81.1% | -220.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.03 | 0.03 |
| Current Ratio | 51.12 | 51.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-63.0M | $-63.0M | $-74.0M | $-70.7M | $-49.6M |
| Returns | |||||
| ROE | -7.5% | -7.5% | -9.9% | -6.0% | -16.1% |
| Valuation | |||||
| P/B | 4.81 | 4.81 | 2.49 | 2.97 | 2.47 |
| Growth & Yield | |||||
| Revenue Growth | -13.5% | -13.5% | -13.4% | 84.8% | — |
| EPS Growth | — | — | -29.7% | 38.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+98.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.01 → n/d
Residual
+98.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.